You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hodgkin Lymphoma, Nivolumab, Ifosfamide, Carboplatin, Etoposide

Showing 1 - 25 of 8,504
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Duarte, California
  • +3 more
Oct 24, 2022

Hodgkin Lymphoma Trial in Saint Petersburg, Irkutsk (Nivolumab, Ifosfamide, Carboplatin)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Pesochny, Russian Federation
  • +2 more
Jul 19, 2021

Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)

Recruiting
  • Classic Hodgkin's Lymphoma
  • Sintilimab
  • +4 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022

Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

Not yet recruiting
  • Mature B-Cell Non-Hodgkin Lymphoma
  • (no location specified)
Sep 6, 2022

B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • (no location specified)
Aug 7, 2023

DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)

Recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Pembroke Pines, Florida
  • +3 more
Jan 23, 2023

Aggressive Non-Hodgkin Lymphoma Trial in Belgium, France (drug, other, procedure)

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • Brugge, Belgium
  • +21 more
Jan 9, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Non-Hodgkin's Lymphoma Trial in New York (Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin,

Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • Etoposide, carboplatin, ifosfamide
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 23, 2022

Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (Ibrutinib, Rituximab, Ifosfamide)

Terminated
Has Results
  • Lymphoma, Non-Hodgkin
  • Los Angeles, California
  • +76 more
Nov 7, 2022

Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

Terminated
Has Results
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Miami, Florida
    University of Miami
Aug 23, 2022

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Relapsed Diffuse Large B-cell Lymphoma, Refractory DLBCL Trial in Worldwide (Polatuzumab Vedotin, Mabthera, Ifosfamide)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +4 more
  • Graz, Austria
  • +62 more
Aug 2, 2022

Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +13 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 18, 2022

Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)

Active, not recruiting
  • Diffuse Large B-cell-lymphoma
  • Saint Louis, Missouri
  • +2 more
Nov 14, 2022

Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)

Recruiting
  • Lymphoma
  • Radiation Therapy
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 9, 2022

DLBCL Unclassifiable, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial in Duarte,

Recruiting
  • Diffuse Large B-Cell Lymphoma Unclassifiable
  • +6 more
  • Duarte, California
  • +1 more
Oct 1, 2021

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)

Active, not recruiting
Has Results
  • CD20 Positive
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 11, 2021

Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Headington, Oxford, United Kingdom
  • +1 more
Nov 2, 2022

Hodgkin's Lymphoma Trial in Houston (Panobinostat, Ifosfamide, Mesna)

Completed
Has Results
  • Hodgkin's Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 10, 2020

Peripheral T-cell Lymphoma Trial in Singapore (Selinexor, ICE Chemotherapy)

Completed
  • Peripheral T-cell Lymphoma
  • Singapore, Singapore
    National Cancer Centre Singapore
Apr 27, 2021

Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Trial in Vancouver (Cyclophosphamide,

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  • Vancouver, British Columbia, Canada
    BC Cancer Agency
Jul 20, 2021

Classic Hodgkin Lymphoma Trial (procedure, biological, drug, other, radiation)

Not yet recruiting
  • Classic Hodgkin Lymphoma
  • Biospecimen Collection
  • +19 more
  • (no location specified)
Jan 6, 2023